Could a Two-Drug combo tame Crohn's in kids?

NCT ID NCT07424040

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will compare two treatments for children with moderate to severe Crohn's disease: infliximab alone or infliximab plus azathioprine. About 154 children will receive one of the two regimens for over a year. The goal is to see if the combination leads to higher remission rates and fewer complications without increasing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
infliximab and azathioprine
What this could lead to
If successful, this could show that combining two drugs helps more children with Crohn's disease reach and stay in remission without extra safety risks.
What could go wrong
This trial hasn't started yet and is relatively small (154 children). It compares existing drugs, so it's not a breakthrough—just a refinement. Side effects like infections or liver issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE IN PEDIATRIC PATIENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • JinHua Maternal & Child Health Care Hospital

    Jinhua, Zhejiang, 321000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Second Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Children's Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First People's Hospital of Yunnan

    Kunming, Yunnan, 650000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.